

ASRS GLOBAL TRENDS IN RETINA

Africa/Middle East



Asia/Pacific




Americas



Europe



2021



ASRS


GLOBAL

TRENDS


I N R E T I N A

Dean Elliott, MD, FASRS

2021



ASRS International Affairs



**Preferences and Trends
(PAT) Survey**

43 societies accepted our invitation;
675 of their members answered the
8th Global Trends in Retina Survey

GLOBAL TRENDS in Retina

International Affairs Committee Staff Liaison

Jennifer Carstens

ASRS PAT Survey Editors

Paul Hahn, MD, PhD, FASRS, *Editor*

Susan Raef, MSMC, *Managing Editor*

Research Consultant and Project Manager

Mindy Schneiderman, PhD



GLOBAL TRENDS in Retina

International Affairs Committee

Dean Elliott, MD, FASRS, Chair

J. Fernando Arevalo, MD, PhD, FACS, FASRS

Alay S. Banker, MD, FASRS

Ehab N. El-Rayes, MD, PhD, FASRS

Marta Figueroa, MD, PhD

Stratos V. Gotzaridis, MBBS, MD

Adnan Tufail, MBBS, MD, FRCOphth



GLOBAL TRENDS in Retina

International Liaison Leaders

J. Fernando Arevalo, MD, FACS, FASRS (Americas)

Alay S. Banker, MD, FASRS (Asia/Pacific)

Ehab N. El-Rayes, MD, PhD, FASRS (Africa/Middle East)

Adnan Tufail, MBBS, MD, FRCOphth (Europe)



Africa/Middle East



ARAB AFRICAN SOCIETY
of Retina Specialists

Arab African Society of Retina Specialists (AASRS)



ESO
EMIRATES SOCIETY OF
OPHTHALMOLOGY

Emirates Society of Ophthalmology



IRANIAN VITREORETINAL SOCIETY

Gulf Retina Group

Iranian Vitreoretinal Society



ISRAELI VITREORETINAL SOCIETY

Israel Vitreoretinal Society



THE JORDAN VITREORETINAL SOCIETY

The Jordan Vitreoretinal Society



الجمعية السعودية لطب العيون
SAUDI OPHTHALMOLOGICAL SOCIETY

Saudi Ophthalmological Society



الجمعية السورية لطب العيون
SYRIAN OPHTHALMOLOGICAL SOCIETY

Syrian Ophthalmological Society



VITREORETINAL SOCIETY OF NIGERIA

Vitreoretinal Society of Nigeria





Asia/Pacific

Association of Vitreo-Retina Specialists of SriLanka



Australian and New Zealand Society of Retinal Specialists



Chinese Ocular Fundus Diseases Society



Indonesia Vitreoretinal Society



Japanese Retina and Vitreous Society



The Korean Retina Society



Malaysian Society of Ophthalmology



Singapore Society of Ophthalmology, Retina Section



Taiwan Retina Society



The Thai Retina Society



Vitreous Retina Society of India



The Vitreo Retina Society of The Philippines



Europe



Austrian Ophthalmological Society

British and Eire Association of Vitreoretinal Surgeons (BEAVRS)

Dutch Society of Vitreoretinal Surgery

Dutch Medical Retina Society

European Vitreoretinal Society

French Society of Retina Specialists

Greek Vitreo-Retinal Society (GVRS)

Italian Vitreoretinal Surgery Society

Rosengren Club—Swedish Vitreoretinal Society

Spanish Retina and Vitreous Society (SERV)

Turkish Ophthalmological Society

Ukranian Alliance of Ophthalmologists



Americas



Argentine Retina and Vitreous Society



Brazilian Retina and Vitreous Society

Canadian Retina Society

Canadian Retina Society



Colombian Retina and Vitreous Association



Mexican Retina Association



Pan-American Retina & Vitreous Society (PRVS)



Peruvian Society of Ophthalmology



Salvadoran Retina and Vitreous Association




Central American Retina and Vitreous Society (SCRV)




Uruguayan Association of Ophthalmology




Which anti-VEGF agent do you prefer for reducing persistent IRF or SRF in wet AMD?




How much recurrent extrafoveal SRF would you tolerate in a recently diagnosed wet-AMD patient on a T&E protocol?




How do you manage persistent CNV (AMD) activity after 8 monthly Eylea injections, VA = 20/50?




In a patient with high-risk PDR and center-involved DME, if you plan to treat the DME with anti-VEGF, do you still recommend PRP?




Does extensive peripheral capillary nonperfusion without NV on FA affect how you manage RVO with macular edema?




When and where do you refer an acute, symptomatic CRAO with a visible embolus at the ONH?




In what % of wet-AMD patients would you use IVT gene therapy that reduced injection need by 80%?




For a patient with a recent macula-off RD with symptoms for < 1 day, when would you operate?




Which procedures do you perform during vitrectomy for a macula-off RD with 1 mid-peripheral break?




What type of IOL would you place in a 35-year-old aphakic patient with no capsular support?




What percentage of your vitrectomies are performed primarily to remove debilitating vitreous opacities?




How do you treat patients with very severe NPDR without DME?




Do you believe patients with wet AMD are being undertreated?




Despite most pivotal anti-VEGF trials studying monthly dosing, why do you favor a T&E or PRN approach?



How often do you perform pneumatic retinopexy?



2021



ASRS

GLOBAL
TRENDS

I N R E T I N A

Thank You
